Symbicort now available as metered-dose inhaler for COPD

Symbicort (formoterol/budesonide) is now available as a pressurised metered-dose inhaler (pMDI) for patients with moderate to severe COPD.

Symbicort contains the long-acting beta2 agonist formoterol and the corticosteroid budesonide, which show additive effects in reducing COPD exacerbations. | SCIENCE PHOTO LIBRARY
Symbicort contains the long-acting beta2 agonist formoterol and the corticosteroid budesonide, which show additive effects in reducing COPD exacerbations. | SCIENCE PHOTO LIBRARY

Further information
View Symbicort drug record
Summary of Product Characteristics
Manufacturer: AstraZeneca
MIMS Respiratory Clinic

Symbicort pMDI provides a metered dose of 200 microgram budesonide and 6 microgram formoterol fumarate dihydrate (corresponding to delivered doses of 160 microgram and 4.5 microgram, respectively). It is indicated in adults with COPD who have a post-bronchodilator FEV1 less than 70% predicted normal and a history of exacerbations despite regular bronchodilator therapy. Two puffs are taken twice daily.

Symbicort was previously only available in the dry powder Turbohaler device.

Pre- and post-dose FEV1

A 6-month randomised, double-blind trial evaluated the effect of budesonide/formoterol pMDI on pre-dose and 1-hour post-dose FEV1 in 1704 patients with moderate to very severe COPD. Participants underwent a 2-week run-in phase and were then treated with budesonide/formoterol pMDI 160/4.5 microgram; budesonide/formoterol pMDI 80/4.5 microgram; budesonide pMDI 160 microgram plus formoterol dry powder inhaler (DPI) 4.5 microgram; budesonide pMDI 160 microgram; formoterol DPI 4.5 microgram; or placebo. All medications were given twice daily.

Improvements in pre-dose FEV1 were significantly greater in patients treated with budesonide/formoterol 160/4.5 microgram twice daily than in those who received formoterol 4.5 microgram alone (p=0.026). Significantly greater improvements were also demonstrated in 1-hour post-dose FEV1 for budesonide/formoterol 160/4.5 microgram versus budesonide 160 microgram alone (p<0.001).

Dyspnoea (assessed with breathlessness diaries) and health-related quality of life scores (based on the St George's Respiratory Questionnaire total score) were significantly improved with budesonide/formoterol 160/4.5 microgram twice daily compared with either agent alone or placebo (p≤0.044 for all).

Long-term use

A 12-month double-blind study (n=1964) randomised COPD patients to receive twice-daily doses of budesonide/formoterol pMDI 160/4.5 microgram, budesonide/formoterol pMDI 80/4.5 microgram, formoterol DPI 4.5 microgram, or placebo.

Patients taking budesonide/formoterol 160/4.5 microgram twice daily experienced greater improvements in pre-dose FEV1 than those taking formoterol alone (p=0.008), and greater improvements in 1-hour post-dose FEV1 than those in the placebo group (p<0.001).

Exacerbation reduction

Another 12-month study randomised 1219 patients to receive budesonide/formoterol pMDI 160/4.5 microgram, budesonide/formoterol pMDI 80/4.5 microgram or formoterol DPI 4.5 microgram, all taken twice daily after an initial 2-week run-in period. Exacerbations, defined as worsening of COPD requiring oral corticosteroids and/or hospitalisation, were analysed.

Compared with the formoterol group, patients in the budesonide/formoterol 160/4.5 microgram twice-daily group experienced a 34.6% reduction in exacerbation rate (p≤0.002). Budesonide/formoterol 160/4.5 microgram prolonged the time to first exacerbation compared with formoterol, corresponding to a 21.2% reduction in hazard ratio (0.788, 95% Cl 0.6390.972; p=0.026).

When exacerbations were defined as worsening of COPD requiring oral corticosteroids, hospitalisation or antibiotic treatment, post-hoc analysis showed that rates were reduced by 25.9% with formoterol/budesonide 160/4.5 microgram twice daily versus formoterol (p≤0.023).

Studies showed that budesonide/formoterol was relatively well tolerated when administered via pMDI. Side-effects similar to those experienced after use of the individual components may occur. The most common effects are tremor and palpitations, which are usually mild and disappear within a few days.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Chronic obstructive pulmonary disease

Effective management of COPD should preserve lung function...

Symbicort SMART dosing regimen

A new dosing regimen, known as SMART (Symbicort Maintenance...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases